Company to showcase breakthrough, multi-platform technology for the treatment of early-stage breast cancer, non-melanoma skin cancer and gynecological cancers at booth #T1
NASHUA, NH and BOSTON, MA (#T1) – April 20, 2017 – iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that updated clinical data on the use of intraoperative radiation therapy (IORT) using the Xoft® Axxent® Electronic Brachytherapy (eBx®) System will be presented during the American Brachytherapy Society (ABS) Annual Meeting in Boston, MA. The Xoft System and its suite of products will also be showcased at the Xoft booth (#T1) from April 21-22, 2017.
“This important data presentation represents a significant milestone for our company in continuing to expand the growing body of research highlighting the Xoft System’s clinical value to patients and clinicians alike,” said Ken Ferry, CEO of iCAD. “As more clinicians report on the safety and efficacy of the Xoft System, their insights continue to validate our commitment to this advanced technology offering tangible benefits to certain women diagnosed with early-stage breast cancer.”
At the meeting, Gary Proulx, M.D., Medical Director, Radiation Oncology at Exeter Hospital will present updated findings on his recent clinical experience treating 94 early-stage breast cancer patients with IORT using the Xoft System in a snap oral presentation entitled “Intraoperative Radiation (IORT) as Adjuvant Radiation Monotherapy for Early-Stage Breast Cancer Patients Treated with Breast Conserving Surgery.”
“Early results from our research suggest that this short course of full dose radiation in a single treatment offers a low rate of local failure and a high rate of excellent cosmesis for properly selected patients. We are happy to report that 100% of patients were very pleased with the treatment experience and treatment outcome on follow up visits,” said Dr. Proulx. “I am very encouraged by the early results of our research that indicate improved quality of life for patients eligible for IORT by greatly reducing the number of treatments patients receive when compared to EBRT.”
Details regarding the presentation by Dr. Proulx are as follows:
Session: Scientific Session: Breast Snap Orals
Date/Time: Friday, April 21, 2017
Time of Presentation: 6:25 – 6:30 pm ET
Publication/Presentation Number: BSOR9
In addition, Ajay Bhatnagar, MD, MBA, Radiation Oncologist at 21st Century Oncology, will participate in a panel discussion and several workshops during the meeting to review his recent clinical experience in treating nonmelanoma skin cancer (NMSC) with the Xoft System. Dr. Bhatnagar will participate in the following discussions during the ABS meeting:
Thursday, April 20, 2017:
- Self-Assessment Module Credit Course
Skin Session I: Multi – Disciplinary Care of Skin Cancer
Moderator: Ajay Bhatnagar, MD, MBA
Time: 10:30 – 11:30 am ET
Friday, April 21, 2017 and Saturday, April 22, 2017:
- Contouring Workshop, Skin Workshop
Time: 4:00 – 6:00 pm ET
The Xoft System is FDA cleared for treatment of cancer anywhere in the body including early-stage breast cancer, gynecological cancer and NMSC.
About Xoft Axxent Electronic Brachytherapy System
The Xoft System is an isotope-free radiation treatment that is FDA cleared, CE marked, and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including treatment of early-stage breast cancer, gynecological cancers and non-melanoma skin cancer. It utilizes a proprietary miniaturized x-ray as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs. The Xoft System requires only minimal shielding and therefore does not require room redesign or construction investment. Minimal shielding also allows medical personnel to remain in the room with the patient during treatment. The mobility of the Xoft System makes it easy to treat patients at multiple locations and to easily store the system when not in use. The Axxent Hub is a cloud-based oncology collaboration software solution that enables centers to monitor treatment workflow and enhance communication between clinical specialists. Xoft is a wholly owned subsidiary of iCAD, Inc. For more information about Xoft visit www.xoftinc.com, like us on Facebook or follow us on Twitter at @xofticad.
About iCAD, Inc.
iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while improving patient outcomes. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers. iCAD’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared and CE marked for use anywhere in the body, including treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments. For more information, visit or www.icadmed.com or www.xoftinc.com.
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Company’s ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “would”, “could”, “consider”, “project”, “estimate”, “will”, “continue”, “anticipate”, “likely”, “seek”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, including the 10-K for the year ended December 31, 2016, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
For iCAD investor relations:
Bob Yedid, (646)-597-6989
For iCAD media inquiries:
Berry & Company Public Relations, LLC
Lynn Granito, 212-253-8881